by Stacey Johnson | Dec 19, 2025
A recent publication on the marketing of stem cell supplements, in the International Society for Stem Cell Research’s (ISSCR) Stem Cell Reports, sparked my curiosity about these products. While I haven’t been able to find a reliable source indicating how long stem...
by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
by Cal Strode | Jul 12, 2023
In 2017, Signals’ blog carnival focused on Right to Try (RTT) legislation – laws that allow patients with life-threatening conditions to ask drugmakers for medicines that have cleared some testing hurdles, but still haven’t been approved by the U.S. Food and Drug...
by Stacey Johnson | Nov 4, 2022
Despite valiant efforts by countless people and organizations, misinformation and a lack of public trust in science continue to be prevalent themes in 2022. Day two of the Till & McCulloch Meetings in Vancouver kicked off with an informative plenary exploring...
Comments